



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/560,533
Applicant : Anna FERNANDEZ SERRAT et al.
Filed : December 13, 2005
TC/A.U. : 1614
Examiner :

Docket No. : 3378-101
Customer No. : 06449
Confirmation No. : 6463

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,
Applicant submits herewith information that the Office may wish
to consider in examination of the subject application. Materials
submitted for consideration are listed on the attached form PTO-
1449.

Respectfully submitted,

By Barbara W. Walker
Barbara W. Walker
Attorney for Applicants
Registration No. 35,400
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known	
Application Number	10/560,533
Filing Date	December 13, 2005
First Named Inventor	Anna FERNANDEZ SERRAT et al.
Group Art Unit	1614
Examiner Name	
Confirmation No.	6463

Sheet

1

of

5

Attorney Docket Number

3378-101

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
		WO	93/22423	A1	MICROCARB INC.	11-11-1993	
		WO	97/27857	A1	MERCK & CO., INC.	08-07-1997	
		WO	97/28115	A1	MERCK & CO., INC.	08-07-1997	
		WO	97/28137	A1	MERCK & CO., INC.	08-07-1997	
		WO	97/28149	A1	MERCK & CO., INC.	08-07-1997	
		WO	97/31907	A1	GLAXO GROUP LIMITED	09-04-1997	
		WO	98/27974	A1	MERCK & CO. INC.	07-02-1998	
		WO	99/04815	A1	YAMANOUCHI PHARMACEUTICAL CO., LTD.	02-04-1999	Ab
		WO	99/19313	A1	DR. REDDY'S RESEARCH FOUNDATION	04-22-1999	
		WO	99/62872	A1	ASTRA AKTIEBOLAG	12-09-1999	
		WO	01/00603	A1	GLAXO GROUP LIMITED	01-04-2001	
		WO	01/79197	A1	NIPPON CHEMIPHAR CO. LTD.	10-25-2001	Ab
		WO	01/25181	A1	EISAI CO., LTD.	04-12-2001	Ab
		WO	02/14291	A1	NIPPON CHEMIPHAR CO., LTD.	02-21-2002	Ab
		WO	02/059098	A1	GLAXO GROUP LIMITED	08-01-2002	

Examiner Signature	/Jeffrey Murray/	Date Considered	03/12/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/560,533
				Filing Date	December 13, 2005
				First Named Inventor	Anna FERNANDEZ SERRAT et al.
				Group Art Unit	1614
				Examiner Name	
Confirmation No.	6463				
Sheet	2	of	5	Attorney Docket Number	3378-101

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Jeffrey Murray/	Date Considered	03/12/2009
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

"For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible."Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>				
				Application Number		10/560,533		
				Filing Date		December 13, 2005		
				First Named Inventor		Anna FERNANDEZ SERRAT et al.		
				Group Art Unit		1614		
				Examiner Name				
				Confirmation No.		6463		
Sheet		3	of	5	Attorney Docket Number			3378-101

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		FAJAS, L., et al., "The Organization, Promoter Analysis, and Expression of the Human PPAR Gene", The Journal of Biological Chemistry, Vol. 272, No. 30, July 25, 1997, pp. 18779-18789						T ²
		FAJAS, L., et al., "PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter", FEBS Letters, 438, 1998, pp. 55-60						
		VAMECQ, J., et al., "Medical significance of peroxisome proliferator-activated receptors", The Lancet, Vol. 354, July 10, 1999, pp. 141-148						
		GRIMALDI, P.A., "The roles of PPARs in adipocyte differentiation", Progress in Lipid Research, 40, 2001, pp. 269-281						
		SCHILLER, P.C., et al., "Inhibition of Gap-Junctional Communication Induces the Trans-differentiation of Osteoblasts...", The Journal of Biological Chemistry, Vol. 276, No. 17, April 27, 2001, pp. 14133-14138						
		LEIBOWITZ, M.D., et al., "Activation of PPAR δ alters lipid metabolism in db/db mice", FEBBS Letters 473, 2000, pp. 333-336						
		OLIVER, Jr., W., et al., "A selective peroxisome proliferator-activated receptor δ agonist promotes...", PNAS, Vol. 98, No. 9, April 24, 2001, pp. 5306-5311						
		MUOIO, D.M., et al., "Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes...", The Journal of Biological Chemistry, Vol. 277, No. 29, July 19, 2002, pp. 26089-26097						
		MUKHERJEE, R., "PPARs: Versatile Targets for Future Therapy for Obesity, Diabetes and Cardiovascular Diseases", Drug News Perspect 15(5), June 2002, pp. 261-267						
		TAN, N.S., et al., "Critical roles of PPAR β/δ in keratinocyte response to inflammation", Genes & Development, 15, 2001, pp. 3263-3277						
		SCHMUTH, M., et al. "Peroxisome Proliferator-Activated Receptor (PPAR)- β/δ Stimulates...", The Journal of Investigative Dermatology, 122, April 2004, pp. 971-983						
		PARK, B.H., et al., "Genetic disruption of PPAR δ decreases the tumorigenicity of human colon cancer cells", PNAS, Vol. 98, No. 5, February 27, 2001, pp. 2598-2603						
Examiner Signature	/Jeffrey Murray/				Date Considered	03/12/2009		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/560,533
				Filing Date	December 13, 2005
				First Named Inventor	Anna FERNANDEZ SERRAT et al.
				Group Art Unit	1614
				Examiner Name	
Confirmation No.	6463				
Sheet	4	of	5	Attorney Docket Number	3378-101

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SHEARER, B.G., et al., "Recent Advances in Peroxisome Proliferator-Activated Receptor Science", Current Medicinal Chemistry, Vol. 10, No. 4, 2003, pp. 267-280	
		TAN, N.S., et al., "Peroxisome proliferator-activated receptor-β as a target for wound healing drugs", Expert Opin. Ther. Targets, 8, (1), 2004, pp. 39-48	
		PEI, L., et al., "Fat's loss is bone's gain", The Journal of Clinical Investigation, Vol. 113, No. 6, March 2004, pp. 805-806	
		BAL-TEMBE, S., et al., "HL 752: A Potent and Long-Acting Antispasmodic Agent", Bioorganic & Medicinal Chemistry, Vol. 5, No. 7, 1997, pp. 1381-1387	
		CANTELO, B., et al., "[(ω-(Heterocyclamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent...", Journal of Medicinal Chemistry, Vol. 37, No. 23, 1994, pp. 3977-3985	
		SOLAR, S., et al., "Selective O-Alkylation of Tyrosine", IBM Research Laboratory, San Jose, CA, NOTES, Vol. 31, June 1966, pp. 1996-1997	
		MITSUNOBU, O., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products", Synthesis, January 1981, pp. 1-28	
		HARLAND, P., et al., "Synthesis of Primary Amines via Alkylation of the Sodium Salt of Trifluoracetamide: An Alternative...", Communications, November 1984, pp. 941-943	
		DAOUD, K.M., et al., "Synthesis of Biologically Active Compounds of Amino Ester Hydrochlorides derived from Substituted-cinchophen", J. Indian Chem. Soc., Vol. 66, May 1989, pp. 316-318	
		AQUINO, C., et al., "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity...", Journal of Medicinal Chemistry, Vol. 39, No. 2, 1996, pp. 562-569	
		MORI, K., et al., "Synthesis of (4E, 8E, 2S, 3R, 2'R)-N-2'-Hydroxyhexadecanoyl-9-Methyl-4,8-Sphingadienine,..." Tetrahedron, Vol. 41, No. 12, 1985, pp. 2369-2377	
Examiner Signature	/Jeffrey Murray/		Date Considered 03/12/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/560,533
				Filing Date	December 13, 2005
				First Named Inventor	Anna FERNANDEZ SERRAT et al.
				Group Art Unit	1614
				Examiner Name	
Confirmation No.	6463				
Sheet	5	of	5	Attorney Docket Number	3378-101

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cité No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		LEHMANN, J., et al., "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated...", The Journal of Biological Chemistry, Vol. 270, No. 22, June 2, 1995, pp. 12953-12956			
		ELBRECHT, A., et al., "L-764406 Is a Partial Agonist of Human Peroxisome...", The Journal of Biological Chemistry, Vol. 274, No. 12, March 19, 1999, pp. 7913-7922			
		WRIGHT, H., et al. "A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor...", The Journal of Biological Chemistry, Vol. No. 275, No. 3, January 21, 2000, pp. 1873-1877			
Examiner Signature	/Jeffrey Murray/			Date Considered	03/12/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./